Deliver Low Risk Patients at 39 Weeks to Prevent Hypertensive Complications?
BACKGROUND AND PURPOSE:
Moussa et al. (Journal of Maternal-Fetal & Neonatal Medicine, 2017) examined the proportion of adverse pregnancy outcomes in deliveries prior to or at ≥39 weeks in uncomplicated singleton nulliparous women (low-risk) versus women with history of preeclampsia in a prior gestation (high-risk)
A secondary analysis from the multicenter trials of low dose aspirin for preeclampsia prevention in 3021 low and 600 high-risk pregnancies
Outcomes were proportions of adverse pregnancy outcomes including:
Hypertensive disorders in pregnancy
Small for gestational age (SGA)
Respiratory distress syndrome
Outcomes were divided into <39 weeks and ≥39 weeks gestational age at delivery
In the low risk group:
12% had hypertensive disorders (58% occurring at ≥39 weeks)
9% neonatal intensive care unit admission (44% occurring at ≥39 weeks)
5.9% SGA (60% occurring at ≥39 weeks)
3.5% respiratory distress syndrome (33% occurring at ≥39 weeks)
0.4% placental abruption (31% occurring at ≥39 weeks)
In the high risk group:
33% had hypertensive disorders (35.5% occurring at ≥39 weeks)
15.5% neonatal intensive care unit admission (16% occurring at ≥39 weeks)
9.2% SGA (24% occurring at ≥39 weeks)
5% respiratory distress syndrome (3% occurring at ≥39 weeks)
2% placental abruption (8.3% occurring at ≥39 weeks)
In the low risk group, the majority of hypertensive disorders occur ≥39 weeks
In contrast, the majority of the high risk group developed hypertensive disorders <39 weeks
The authors suggest that to prevent adverse events related to hypertensive disorders, a policy of delivery / induction of low risk women at 39 weeks may be well advised
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan